NORDIC | BIOTECH & HEALTHCAREYour insights to listed Danish & Nordic biotech & healthcare stocks.
In the past week, Ascendis Pharma presented their 2030 vision, Biosergen changed CEO, Fluoguide provided an update on FG001, Zealand Pharma raised more than a billion DKK, while Genmab and Zealand Pharma received new price targets.
9 of the 20 listed Danish biotech companies published news. 10 of the 20 companies had a positive share price development the past week and 11 companies have had a positive share price performance year-to-date.
ExpreS2ion Biotech is the best performing stock year-to-date with a 62% return and Lidds was the best investment last week with a return of 102%.
Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you to invest more sustainably in the businesses of tomorrow.
DANISH COMPANY NEWS
Ascendis Pharma Introduces Vision 2030 (Link)
Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor (Link)
Cessatech announces TO2 warrant exercise price and start of exercise period (Link)
Cessatech announces the start of the exercise period for warrants of series TO2 (Link)